Vyome (NASDAQ:HIND) Releases Earnings Results

Vyome (NASDAQ:HIND) issued its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, Zacks reports.

Vyome Price Performance

Shares of HIND traded down $0.03 during midday trading on Wednesday, reaching $2.22. The stock had a trading volume of 11,490 shares, compared to its average volume of 360,629. The company has a market cap of $15.58 million, a price-to-earnings ratio of -0.18 and a beta of 1.48. The company’s fifty day simple moving average is $2.17 and its two-hundred day simple moving average is $2.32. Vyome has a 1-year low of $1.75 and a 1-year high of $18.60.

Hedge Funds Weigh In On Vyome

A hedge fund recently bought a new stake in Vyome stock. Geode Capital Management LLC purchased a new stake in Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome at the end of the most recent reporting period. Institutional investors and hedge funds own 22.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HIND. Litchfield Hills Research started coverage on shares of Vyome in a research report on Monday, May 4th. They issued a “buy” rating on the stock. Zacks Research upgraded shares of Vyome to a “hold” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $15.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.